MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Cellectar Biosciences Inc

Отворен

0.3 3.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.28

Максимум

0.31

Ключови измерители

By Trading Economics

Служители

11

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+222.58% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-3.4M

10M

Предишно отваряне

-3.15

Предишно затваряне

0.3

Cellectar Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.12.2024 г., 18:44 ч. UTC

Значими двигатели на пазара

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Сравнение с други в отрасъла

Ценова промяна

Cellectar Biosciences Inc Прогноза

Ценова цел

By TipRanks

222.58% нагоре

12-месечна прогноза

Среден 1 USD  222.58%

Висок 1 USD

Нисък 1 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Cellectar Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Финанси

$

Относно Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.